Determination of 10B in lymphoma human cells after boron carrier treatment: Comparison of 10BPA and immuno-nanoparticles

Marco Giovanni Persico, Patrizia Chiari, Raffaela Biesuz, Giancarla Alberti

Research output: Contribution to journalArticle


Current cancer treatments lead to insufficient distribution of therapeutic agents in tumor cells due to their lack of selectivity often causing adverse effects in the normal cell uptake of the drug. The challenge is to design therapeutic drugs able to maximize the treatment of malignant cancers while minimizing their adverse effects. In this study, 10B incorporation in the B chronic lymphocytic leukemia cell line MEC-1 was investigated. The cells were treated with l-p-10borophenylalanine (10BPA) and 10boron immuno-nanoparticles (BNPs) loaded with 10BPA with or without the anti-CD20 monoclonal antibody for different contact times. The uptake of 10B by the cells was determined by the inductively coupled plasma mass spectrometry (ICP-MS) after acid mineralization. To obtain accurate and consistent data, the analytical procedure was optimized using factorial experimental design. It was observed that BNP loaded with 10BPA and anti-CD20 represents the best carrier system for 10B in B cells for long time (>10 h) whereas 10BPA seems to be the top drug for short time (<4 h) procedures.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalChemical Papers
Issue number2
Publication statusPublished - Feb 2014


  • boron-10 carrier
  • human tumour cells
  • immuno-nanoparticles
  • in vitro experiments

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)
  • Biochemistry
  • Industrial and Manufacturing Engineering
  • Materials Chemistry

Fingerprint Dive into the research topics of 'Determination of 10B in lymphoma human cells after boron carrier treatment: Comparison of 10BPA and immuno-nanoparticles'. Together they form a unique fingerprint.

  • Cite this